PRE-CONFERENCE WORKSHOPS │Tuesday September 3, 2024
|
Register your interest to attend and take part in key discussions that will shape the CDx industry. *Attendance is subject to approval by the hosting partner. The Event Manager Molly Mahiques will be in touch to confirm your attendance once you have been confirmed by the host. |
8:00 am - 11:30 am | Tackle Biomarkers and Engage with Leading Experts hosted by Foundation Medicine
This session will take place at the FMI facility, further details will be provided upon attendance confirmation by the Event Manager
8:00 am Hot Breakfast, Coffee & Networking
8:45 am Introduction & Welcome
9:00 am Panel Discussion: Tackling Hard Biomarkers
Synopsis
• Panelist Insights: Assessing Challenging Biomarkers
• Enrollment Strategies & Key Considerations for Novel Biomarkers
• Overcoming Challenges in Biomarker Development with Diagnostic Partners
9:30 am Breakout tables:
Real World Data Solutions
CDx Innovations
(Heme, RNA, CGDB)
ctDNA Monitoring
Cancer Vaccines
& Non-Oncology
Services
New Biomarkers (CH
Prediction, Copy
Number Calling)
New Partner Services
Lab
10:00 am Comfort Break & Coffee
10:15 am Delving into Personalized Cancer Vaccines & Non-Oncology Plans
10:45 am Closing Remarks
11:15 am End of Thought Leadership Workshop with Foundation Medicine
11:30 am - 3:00 pm | The CDx Development Journey - From Concept to Commercialization in Partnership with Roche
11:30 am Lunch & Networking
12:15 pm Opening Remarks – CDx Journey Overview
12:30 pm Discovery Overview – Transitioning from Research to IVD
12:45 pm Development Overview – Assay & Algorithm Evolution
1:00 pm CDx Commercialization Overview – Partnering for Success
1:15 pm Digital Pathology Overview
1:30 pm Comfort Break & Coffee
1:45 pm Deep Dive Breakout Sessions – Stamp your passport here!
Synopsis
Make your way around the tables for comprehensive discussions into CDx development, from concept to commercialization to accelerate your pipelines
Early Biomarker Discovery Roundtable
Dr. Tim Ritty, Senior Marketing Manager, Clinical R&D, US, Roche
CDx Development Roundtable
Katie McArthur, Project Leader, Roche
Hisani Madison, Vice President, Precision Medicine, PathAI
Commercialization Roundtable
Jeff Pearson, US Pharma Partnering Lead, Roche
Paul Gerrard, Head of Global Market Access & Reimbursement, PathAI
Digital Pathology & AI Roundtable
Mike Rivers, Vice President, Digital Pathology, Roche
Ben Glass, Vice President, Product & Translational Research, PathAI
2:45 pm Closing Remarks – Time to Collect Your Roche Swag!
3:00 pm Workshop Close
3:00 pm - 6:30 pm | Considerations for Gene Therapy CDx Development and Antibody Drug Conjugate (ADC) CDx Development with Quest
3:00 pm Afternoon Refreshments & Registration
3:30 pm Opening Remarks
3:40 pm Fireside Chat: Expanding the Realms of Drug/Diagnostic Co-Development
4:30 pm Networking Break
4:45 pm Considerations for Gene therapy CDx Development
5:15 pm Antibody Drug Conjugate (ADC) CDx Development
6:15 pm Closing Remarks
6:30 pm End of Thought Leadership Workshop with Quest Diagnostics
7:00 pm - 9:30 pm | Leveraging Real World Data to Enhance End-to-End CDx Development Strategy & Execution in Partnership with Guardant Health
7:00 pm Registration & Welcome
7:20 pm Set Up the Problem: Discuss the Unmet Needs & Challenges with CDx Development Today
7:25 pm An Overview of Guardant Health’s CDx capabilities, US & Global
7:30 pm Introduction to the GuardantINFORM Platform Featuring an Extensive Clinical-Genomic Liquid Biopsy Dataset of Advanced Cancer Patients
Synopsis
• An overview of GuardantINFORM, our CGDB with over 420K unique patients and the largest serial database of molecular insights
• Thread the needle on how GuardantINFORM’s Real-World Data can enhance and support each step of the CDx development journey that help solve for today’s challenges
7:35 pm Starter Served
7:55 pm Deeper Dive into Specific use Cases Including
Synopsis
• Supporting biomarker discovery through hypothesis validation
• Accelerating trial recruitment through referrals- Synthetic control arm development (in partnership with ConcertAI)
• Commercial insights to inform launch strategy